Nemysis Ltd has market authorisation from the European Commission for its bioavailable iron in nanoparticles, for human oral intake, to relieve the symptoms of iron deficiency. The company also has a novel enzyme therapy at R&D stage for gluten intolerance (Celiac Disease & NCG Sensitivity) and a delivery platform (EDA Matrix) to transport small proteins & molecules safely through the gastric environment.
